<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03847051</url>
  </required_header>
  <id_info>
    <org_study_id>EPIMix pediatric</org_study_id>
    <nct_id>NCT03847051</nct_id>
  </id_info>
  <brief_title>EPIMix Versus CT Brain Pediatric Study</brief_title>
  <official_title>EPIMix (Echo Planar Imaging Mix) Versus CT Brain Pediatric Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stockholm county council (SLL ALF project)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Swedish Childhood Cancer Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the diagnostic feasibility and diagnostic performance of a new fast
      MR sequence EPIMix for neuroradiological evaluation in comparison to computed tomography of
      brain in pediatric population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to assess the feasibility of fast MR sequence for neuroradiological evaluation
      in comparison to computed tomography of brain in pediatric population. Imaging quality is
      analysed with regards to artefacts and lesion conspicuity as well as its diagnostic potential
      in rendering a probable diagnosis. The primary study aim is to define feasibility and the AUC
      for diagnostic performance of minute MRI compared to computed tomography.

      Included patients are children age 4-18 with suspicion of cerebral pathology with referral to
      elective computed tomography of the brain.

      Study participants are in addition to computed tomography investigated during same day at 3T
      MR.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerance of a new fast MR method in children</measure>
    <time_frame>At 0 hours</time_frame>
    <description>Number of aborted MR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic potential</measure>
    <time_frame>At 0 hours</time_frame>
    <description>Diagnostic accuracy to categorize scan as normal or abnormal on a five point Likert scale (1 - definitely normal, 2 - Probably normal, 3 - Indeterminate, 4 - Probably abnormal, 5 - Definitely abnormal) compared to abnormal/normal brain CT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lesion classification</measure>
    <time_frame>At 0 hours</time_frame>
    <description>Classification into disease categories (Neoplastic, Ischemic, Hemorrhagic, Infection, Neuroinflammation, Hydrocephalus, Congenital malformation, Indeterminate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion location determination</measure>
    <time_frame>At 0 hours</time_frame>
    <description>Anatomical localization of abnormality (Cerebrum, Cerebellum, Brainstem, Intraventricular, Subarachnoid space including basal cisterns, Intra-orbital, Skull/Skull base/dural, Other)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic imaging quality</measure>
    <time_frame>At 0 hours</time_frame>
    <description>Diagnostic imaging quality (5 point Likert scale; 1 - Excellent diagnostic imaging quality, 2 - Good diagnostic imaging quality, 3 - Sufficient diagnostic imaging quality, 4 - Restricted diagnostic imaging quality, 5 - Poor diagnostic imaging quality)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion description</measure>
    <time_frame>At 0 hours</time_frame>
    <description>For example effect on brain parenchyma and size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic confidence</measure>
    <time_frame>At 0 hours</time_frame>
    <description>Five point Likert scale (Very confident, Predominantly confident, Fairly confident, Only slightly confident, Not at all confident)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical diagnostic summary report</measure>
    <time_frame>At 0 hours</time_frame>
    <description>Text (one sentence summary of the finding including type of lesion and location)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to rule out diseases</measure>
    <time_frame>At 0 hours</time_frame>
    <description>A list of diseases. Number of positive versus negative cases for each investigation (including: Tumor, Abscess, Parenchymal Haemorrhage, Acute Ischemia, Hydrocephalus, Neuroinflammation, Subarachnoid hemorrhage, Extraaxial fluid collection)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Artefacts</measure>
    <time_frame>At 0 hours</time_frame>
    <description>Artefacts and impact (Motion, Beam hardening, Other) defined as; Not present, Not affecting diagnostic confidence, Degrading diagnostic confidence)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Brain Diseases</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Brain MRI without intravenous contrast</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Child with indication for elective brain CT.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 4-18 years.

          -  Patient with suspicion of cerebral pathology.

          -  Referral to elective brain CT study.

        Exclusion Criteria:

          -  CT planned with sedation

          -  known previous cerebral pathology (follow up study)

          -  Emergency CT

          -  Aborted MR exam
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Falk Delgado, MD, PhD</last_name>
    <phone>+46851775410</phone>
    <email>anna.falk-delgado@sll.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Falk Delgado, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 12, 2019</study_first_submitted>
  <study_first_submitted_qc>February 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Anna Falk Delgado</investigator_full_name>
    <investigator_title>Principal Investigator, Medical doctor, PhD, Specialist in Neuroradiology</investigator_title>
  </responsible_party>
  <keyword>MRI (magnetic resonance imaging)</keyword>
  <keyword>Neuroradiology</keyword>
  <keyword>EPIMix (Echo planar imaging mix)</keyword>
  <keyword>Multicontrast EPI (echo planar imaging)</keyword>
  <keyword>Clinical validation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

